Shots:
- The EC has granted approval to the company’s Wyost and Jubbonti, biosimilar of Xgeva and Prolia (denosumab), across the EU for treating same indications as that of Xgeva and Prolia incl. cancer-related bone disease & osteoporosis, respectively. Their launch is anticipated from Nov 2025 onwards
- The EC’s approval was supported by the clinical evaluations verifying the similarity in safety, effectiveness and quality of biosimilars with their reference drugs
- Wyost and Jubbonti consist of denosumab as an active ingredient and a human mAb IgG2 that attaches with RANKL to prevent RANK activation on osteoclasts and their precursors, inhibiting osteoclast formation, function & survival. This reduces bone resorption in both cortical as well as trabecular bone
Ref: Sandoz | Image: Sandoz | Press Release
Related News:- Alvotech Collaborates with Dr. Reddy’s to Commercialize AVT03 (Biosimilar, Prolia & Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
